Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine - New York Presbyterian Hospital, New York, NY, USA.
Adv Exp Med Biol. 2018;1100:111-125. doi: 10.1007/978-3-319-97746-1_7.
Monitoring measurable (minimal) residual disease (MRD) in acute myeloid leukemia (AML) has greatly increased our ability to assess chemosensisitivity to treatment as well as the duration of treatment responses. There is strong evidence to support its prognostic value for long-term outcomes at different time points and across assays and targets. It's role as a surrogate endpoint to define risk-adapted strategies is still under evaluation. In this chapter, we will discuss the definition of MRD in AML, the potential contribution of leukemia stem cells (LSCs) to MRD and we will review all the current approaches to assess residual disease including the 2018 European Leukemia Network (ELN) working group recommendations for MRD standardization in AML. In addition, a summary of MRD studies associated to prognosis will be described.
监测急性髓系白血病（AML）中的可测量（最小）残留疾病（MRD）极大地提高了我们评估化疗敏感性和治疗反应持续时间的能力。有强有力的证据支持其在不同时间点、不同检测方法和靶点的预后价值。它作为替代终点来定义风险适应性策略的作用仍在评估中。在这一章中，我们将讨论 AML 中 MRD 的定义，白血病干细胞（LSCs）对 MRD 的潜在贡献，我们将回顾所有目前评估残留疾病的方法，包括 2018 年欧洲白血病网络（ELN）工作组对 AML 中 MRD 标准化的建议。此外，还将描述与预后相关的 MRD 研究摘要。
